NCT05702034进行中（未招募）3 期
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 12,523
- 试验地点
- 1,562
- 主要终点
- Time to First Occurrence of Ischemic Stroke
研究概览
简要总结
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ischemic Stroke: a neurological deficit attributable to an acute brain infarction and national institute of health stroke score scale (NIHSS) score less than or equal to (<=) 7 and at least 1 of the following: persistent signs or symptoms of the ischemic event at the time of randomization, or acute, ischemic brain lesion determined by standard-of-care neuroimaging, or participant underwent thrombolysis or thrombectomy, or transient ischemic attack (TIA): acute onset neurological deficit attributable to focal ischemia of the brain by history or examination, with complete symptom resolution of the deficit and no brain infarction on neuroimaging (example, computed tomography (CT) scan or magnetic resonance imaging (MRI), performed as part of standard medical practice), and ABCD2 Score greater than or equal to (>=) 6
- •Participants will be randomized as soon as possible after determining eligibility and within 48 hours of onset of event.
- •Current or planned antiplatelet treatment per international and/or local guidelines. If acetyl salicylic acid (ASA) is used, it will be limited to low dose (75 to 100 milligrams (mg)/day). Loading dose of antiplatelet agents (including ASA) are allowed per standard-of-care
- •A female participant must agree not to be pregnant, breastfeeding, or planning to become pregnant until 4 days (5 half lives) after the last dose of study intervention
- •Willing and able to adhere to the lifestyle restrictions specified in this protocol
排除标准
- •Prior history of intracranial hemorrhage except subarachnoid hemorrhage greater than (>) 1 year prior with adequate treatment
- •The index stroke or TIA is considered to have a cardio-embolic etiology based on local standard-of-care investigations and for which guidelines recommend anticoagulation
- •The index stroke or TIA considered to have another known cause, not related to athero-thrombotic sources (treatment of acute stroke trial [TOAST] Other Determined Etiology), based on local standard-of-care investigations
- •Increased risk of bleeding, including clinically significant bleeding within the previous 3 months or known bleeding diathesis or known activated partial thromboplastin time (aPTT) prolongation or spinal cord hemorrhage or retinal hemorrhage
- •Current active liver disease, eg, acute hepatitis, known cirrhosis, including participants receiving antiviral treatment for hepatitis
- •Known allergies, hypersensitivity, or intolerance to milvexian or its excipients
研究组 & 干预措施
Placebo
Placebo Comparator
Participants after an acute ischemic stroke or high-risk TIA who are receiving antiplatelet therapy standard-of-care (SAPT or DAPT) will receive placebo orally twice daily.
干预措施: Placebo (Drug)
Milvexian
Experimental
Participants after an acute ischemic stroke or high-risk transient ischemic attack (TIA) who are receiving antiplatelet therapy standard-of-care (SAPT [single antiplatelet therapy] or DAPT [dual antiplatelet therapy]) will receive milvexian 25 milligrams (mg), orally, twice daily.
干预措施: Milvexian (Drug)
结局指标
主要结局
Time to First Occurrence of Ischemic Stroke
时间窗: Up to global targeted endpoint date (approximately 41 months)
Time to first occurrence of ischemic stroke will be reported.
次要结局
- Time to First Occurrence of any Component of the Composite of Cardiovascular Death (CVD), Myocardial Infraction (MI), or Ischemic Stroke(Up to global targeted endpoint date (approximately 41 months))
- Time to First Occurrence of any Component of Major Adverse Vascular Events (MAVE)(Up to global targeted endpoint date (approximately 41 months))
- Time to First Occurrence of Ischemic Stroke(Up to Day 90)
研究者
研究点 (1562)
Loading locations...
相似试验
已完成
3 期
A Study of Milvexian in Participants After a Recent Acute Coronary SyndromeAcute Coronary SyndromeNCT05754957Janssen Research & Development, LLC14,194
进行中（未招募）
3 期
A Study of Milvexian Versus Apixaban in Participants With Atrial FibrillationAtrial FibrillationNCT05757869Janssen Research & Development, LLC20,284
已完成
1 期
A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy ParticipantsHealthyNCT04543383Janssen Research & Development, LLC52
已完成
3 期
A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast CancerTriple Negative Breast CancerNCT02032277AbbVie634
已完成
3 期
PPAR - Combination With MetforminDiabetes MellitusNCT00162240Bristol-Myers Squibb534